AI Article Synopsis

  • Heart failure (HF) is a complex condition affecting many individuals worldwide, and only about 50% of patients benefit from standard treatments, highlighting the need to explore its molecular differences.
  • A study investigated epigenetic factors in end-stage HF patients, analyzing DNA methylation patterns in cardiac biopsies from men receiving left ventricular assist devices (LVAD), revealing distinct methylation signatures based largely on race.
  • The findings suggest that African American patients have a higher mortality rate post-LVAD compared to Caucasian patients, possibly linked to socioeconomic disparities, indicating a need for further research into how these factors impact heart failure outcomes.

Article Abstract

Heart failure (HF) is a multifactorial syndrome that remains a leading cause of worldwide morbidity. Despite its high prevalence, only half of patients with HF respond to guideline-directed medical management, prompting therapeutic efforts to confront the molecular underpinnings of its heterogeneity. In the current study, we examined epigenetics as a yet unexplored source of heterogeneity among patients with end-stage HF. Specifically, a multicohort-based study was designed to quantify cardiac genome-wide cytosine-p-guanine (CpG) methylation of cardiac biopsies from male patients undergoing left ventricular assist device (LVAD) implantation. In both pilot ( = 11) and testing ( = 31) cohorts, unsupervised multidimensional scaling of genome-wide myocardial DNA methylation exhibited a bimodal distribution of CpG methylation found largely to occur in the promoter regions of metabolic genes. Among the available patient attributes, only categorical self-identified patient race could delineate this methylation signature, with African American (AA) and Caucasian American (CA) samples clustering separately. Because race is a social construct, and thus a poor proxy of human physiology, extensive review of medical records was conducted, but ultimately failed to identify covariates of race at the time of LVAD surgery. By contrast, retrospective analysis exposed a higher all-cause mortality among AA (56.3%) relative to CA (16.7%) patients at 2 yr following LVAD placement ( = 0.03). Geocoding-based approximation of patient demographics uncovered disparities in income levels among AA relative to CA patients. Although additional studies are needed, the current analysis implicates cardiac DNA methylation as a previously unrecognized indicator of socioeconomic disparity in human heart failure outcomes. A bimodal signature of cardiac DNA methylation in heart failure corresponds with racial differences in all-cause mortality following mechanical circulatory support. Racial differences in promoter methylation disproportionately affect metabolic signaling pathways. Socioeconomic factors are associated with racial differences in the cardiac methylome among men with end-stage heart failure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163657PMC
http://dx.doi.org/10.1152/ajpheart.00036.2021DOI Listing

Publication Analysis

Top Keywords

heart failure
20
dna methylation
16
cardiac dna
12
racial differences
12
socioeconomic disparity
8
differences cardiac
8
methylation
8
men end-stage
8
end-stage heart
8
cpg methylation
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!